Mirum Pharmaceuticals is trading 4.0% down now at $78.17, with no specific catalyst identified; broader biotech weakness may be contributing. - No company-specific announcement or event dated October 6, 2026, was identified as the cause. - The supplied sector context reports XBI down 2.50%, which may be contributing but does not establish a catalyst for Mirum’s larger decline. - A previously reported FDA request for a Phase 3 sclerosing cholangitis study was not identified as the reason for this session’s move.